46 GHP Q4 2023 Aug23390 Fairtility stands out for its revolutionary CHLOE™ platform in this year’s Global Excellence Awards. The company’s commitment to improving IVF outcomes through transparent and explainable AI, through innovation, and by focusing on personalised care sets it apart, reshaping the landscape of in vitro fertilisation (IVF) with a no-nonsense approach. Recognised as our Most Innovative IVF Software Solutions Provider 2023, we see what innovations and high-quality features are available from Fairtility. “The name “Chloe” has a Greek origin meaning of “green sprouts” which represents blooming and fertility.” Fairtility, a pioneer in reproductive care, is making significant strides through its innovative CHLOE™ platform, an AI-powered software designed to support clinicians and patients on their journey to parenthood. Unlike other solutions, CHLOE™ stands out as the first and only transparent AI-based decision support system, providing unparalleled visibility to enhance decision making for improved IVF outcomes. Founded on unwavering principles, Fairtility’s core values, including transparency, reliability, and trust in IVF technology, have remained consistent since its establishment. The company collaborates with large fertility networks, encompassing private clinics and hospital-affiliated fertility centres with high IVF cycle volumes. Fairtility’s overarching mission is to address the fertility health crisis and challenges associated with an ageing population, aligning with concerns expressed by the World Health Organisation. CHLOE EQ™, a component of Fairtility’s groundbreaking platform, supports embryo selection in the IVF process based on explainable AI predictions. In addition, it streamlines embryologist workflows, automates embryo annotation, and seamlessly integrates with clinic Electronic Medical Records (EMRs) among others. By doing so, CHLOE™ empowers practitioners, augmenting clinical decision-making and facilitating more personalised treatment approaches and a more transparent communication with the patients. Fairtility’s unique approach extends beyond its technological innovations. The company actively promotes transparency, collaboration, and education, core values that advance the field of reproductive care, particularly in the increasing hype surrounding AI. Fairtility pioneered the AI Academy, an objective education platform for professionals by experts in AI and fertility, opening up the discussion about AI in the reproductive care space. Topics such as the potential of AI in this field, current availability, how to understand this new “category” and apply critical reading when being presented with research, as well as emphasizing the importance of transparency and adherence to strict guidelines and regulations. The leadership team at Fairtility play a pivotal role in the company’s industry prominence. Led by CEO and co-founder Eran Eshed, a seasoned professional with a background in management, entrepreneurship, and tech c-suite experience, he leads a team that brings together diverse expertise. Medical leaders such as Chief Medical Officer Prof., Assaf Ben Meir, MD and Chief Clinical Officer, Dr. Cristina Hickman, PhD., contribute extensive knowledge in reproductive endocrinology, infertility, and clinical embryology. This blend of skills ensures that Fairtility’s solutions are technologically advanced and firmly rooted in sound medical principles and the latest developments. Fairtility’s uniqueness in the industry lies in CHLOE™’s ability to combine AI-driven analysis with understandable biological data. The platform goes beyond providing a score, offering transparent AI that fosters trust between clinic staff and patients. This trust is pivotal in managing expectations and building solid relationships within the reproductive care ecosystem. With tens of clinics working with CHLOE EQ, Fairtility is poised to disrupt and innovate within the industry over the next five years. They focus on transparency, efficiency, patient-centricity, and personalised care to enhance patient outcomes, alleviate healthcare professional burdens, and expand access to fertility treatments. The company emphasises the importance of understanding the role of Machine Learning (ML) and AI transparently and securely to foster progress in IVF. With its mission of achieving innovation, transparency, and patient-centric care, Fairtility is set to shape the future of reproductive healthcare. As we look ahead, Fairtility is set to redefine the benchmarks in reproductive healthcare, covering the entire spectrum from early health assessment to comprehensive assisted reproductive technology solutions. The focus remains on transparency, efficiency, patientcentricity, and personalised care, charting a course toward enhanced patient outcomes and a transformed future for fertility treatments. Fairtility is not just rewriting the narrative; it’s leading the charge in shaping the future of reproductive healthcare. In conclusion, Fairtility stands at the forefront of Personalised Health Care (PHC), leveraging cutting-edge science, data analysis, and technology to usher in breakthroughs and enhance outcomes in IVF. We will definitely be keeping an eye on how the company progresses and what steps are in place as the industry and technology continue to advance. When it comes to helping people, it is always fascinating to see how those companies doing good for others can progress. Company: Fairtility Web Address: fairtility.com Meet CHLOE
RkJQdWJsaXNoZXIy MTUyMDQwMA==